PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [ 177 Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated f...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2021-12, Vol.48 (13), p.4350-4368 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4368 |
|---|---|
| container_issue | 13 |
| container_start_page | 4350 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 48 |
| creator | Uijen, M. J. M. Derks, Y. H. W. Merkx, R. I. J. Schilham, M. G. M. Roosen, J. Privé, B. M. van Lith, S. A. M. van Herpen, C. M. L. Gotthardt, M. Heskamp, S. van Gemert, W. A. M. Nagarajah, J. |
| description | In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [
177
Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [
177
Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described. |
| doi_str_mv | 10.1007/s00259-021-05433-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8566635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2540723820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-1695b019289e68a3a8a01c07f14afe1d5649512fec115a0ac09fef73d1c013ef3</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi1UREvhD3BAlrhwaGBsx0nMoVJV8SUVgQScrVnH3nXJ2qmdUPUX8Ldx2LJ8HHryaOaZ1zPzEvKEwQsG0L7MAFyqCjirQNZCVNf3yBFrmKpa6NTBPm7hkDzM-RKAdbxTD8ihqBkHpvgR-fHp84czmrD3cfBrDD2dNjbheENdTDSXZMnM25gyjUullDHQMcU84WSpwWBsekVXaL6tU5xDf0LjOMY0zcFP3uYTajY4DDasl3jRdz7liZrBB29woMkudH5E7jscsn18-x6Tr29efzl_V118fPv-_OyiMpKLqWKNkqtl8k7ZpkOBHQIz0DpWo7Osl02tJOPOGsYkAhpQzrpW9AViwjpxTE53uuO82tre2DAlHPSY_BbTjY7o9b-V4Dd6Hb_rTjZNI2QReH4rkOLVbPOktz4bOwwYbJyz5rKGlouOQ0Gf_YdexjmFsl6hFG8b0cEiyHeUKUfNybr9MAz04rPe-ayLz_qXz_q6ND39e419y29jCyB2QC6lcvz05-87ZH8CTjK29w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2592763805</pqid></control><display><type>article</type><title>PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Uijen, M. J. M. ; Derks, Y. H. W. ; Merkx, R. I. J. ; Schilham, M. G. M. ; Roosen, J. ; Privé, B. M. ; van Lith, S. A. M. ; van Herpen, C. M. L. ; Gotthardt, M. ; Heskamp, S. ; van Gemert, W. A. M. ; Nagarajah, J.</creator><creatorcontrib>Uijen, M. J. M. ; Derks, Y. H. W. ; Merkx, R. I. J. ; Schilham, M. G. M. ; Roosen, J. ; Privé, B. M. ; van Lith, S. A. M. ; van Herpen, C. M. L. ; Gotthardt, M. ; Heskamp, S. ; van Gemert, W. A. M. ; Nagarajah, J.</creatorcontrib><description>In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [
177
Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [
177
Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-021-05433-w</identifier><identifier>PMID: 34120192</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antigens ; Brain cancer ; Breast cancer ; Cardiology ; Computed tomography ; Dipeptides ; Glioblastoma ; Hepatocellular carcinoma ; Heterocyclic Compounds, 1-Ring ; Humans ; Imaging ; Immunohistochemistry ; Kidney cancer ; Lung cancer ; Lung carcinoma ; Lutetium isotopes ; Male ; Medical imaging ; Medicine ; Medicine & Public Health ; Nuclear Medicine ; Oncology ; Oncology – General ; Oral cancer ; Orthopedics ; Patients ; Positron emission ; Positron Emission Tomography Computed Tomography ; Prostate cancer ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - radiotherapy ; Prostatic Neoplasms, Castration-Resistant ; Radioisotopes ; Radiology ; Renal cell carcinoma ; Review ; Review Article ; Salivary gland ; Salivary glands ; Side effects ; Solid tumors ; Therapy ; Thyroid cancer ; Tomography ; Tumors</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2021-12, Vol.48 (13), p.4350-4368</ispartof><rights>The Author(s) 2021</rights><rights>2021. The Author(s).</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-1695b019289e68a3a8a01c07f14afe1d5649512fec115a0ac09fef73d1c013ef3</citedby><cites>FETCH-LOGICAL-c523t-1695b019289e68a3a8a01c07f14afe1d5649512fec115a0ac09fef73d1c013ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-021-05433-w$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-021-05433-w$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34120192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uijen, M. J. M.</creatorcontrib><creatorcontrib>Derks, Y. H. W.</creatorcontrib><creatorcontrib>Merkx, R. I. J.</creatorcontrib><creatorcontrib>Schilham, M. G. M.</creatorcontrib><creatorcontrib>Roosen, J.</creatorcontrib><creatorcontrib>Privé, B. M.</creatorcontrib><creatorcontrib>van Lith, S. A. M.</creatorcontrib><creatorcontrib>van Herpen, C. M. L.</creatorcontrib><creatorcontrib>Gotthardt, M.</creatorcontrib><creatorcontrib>Heskamp, S.</creatorcontrib><creatorcontrib>van Gemert, W. A. M.</creatorcontrib><creatorcontrib>Nagarajah, J.</creatorcontrib><title>PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [
177
Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [
177
Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.</description><subject>Antigens</subject><subject>Brain cancer</subject><subject>Breast cancer</subject><subject>Cardiology</subject><subject>Computed tomography</subject><subject>Dipeptides</subject><subject>Glioblastoma</subject><subject>Hepatocellular carcinoma</subject><subject>Heterocyclic Compounds, 1-Ring</subject><subject>Humans</subject><subject>Imaging</subject><subject>Immunohistochemistry</subject><subject>Kidney cancer</subject><subject>Lung cancer</subject><subject>Lung carcinoma</subject><subject>Lutetium isotopes</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nuclear Medicine</subject><subject>Oncology</subject><subject>Oncology – General</subject><subject>Oral cancer</subject><subject>Orthopedics</subject><subject>Patients</subject><subject>Positron emission</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Prostatic Neoplasms, Castration-Resistant</subject><subject>Radioisotopes</subject><subject>Radiology</subject><subject>Renal cell carcinoma</subject><subject>Review</subject><subject>Review Article</subject><subject>Salivary gland</subject><subject>Salivary glands</subject><subject>Side effects</subject><subject>Solid tumors</subject><subject>Therapy</subject><subject>Thyroid cancer</subject><subject>Tomography</subject><subject>Tumors</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1v1DAQhi1UREvhD3BAlrhwaGBsx0nMoVJV8SUVgQScrVnH3nXJ2qmdUPUX8Ldx2LJ8HHryaOaZ1zPzEvKEwQsG0L7MAFyqCjirQNZCVNf3yBFrmKpa6NTBPm7hkDzM-RKAdbxTD8ihqBkHpvgR-fHp84czmrD3cfBrDD2dNjbheENdTDSXZMnM25gyjUullDHQMcU84WSpwWBsekVXaL6tU5xDf0LjOMY0zcFP3uYTajY4DDasl3jRdz7liZrBB29woMkudH5E7jscsn18-x6Tr29efzl_V118fPv-_OyiMpKLqWKNkqtl8k7ZpkOBHQIz0DpWo7Osl02tJOPOGsYkAhpQzrpW9AViwjpxTE53uuO82tre2DAlHPSY_BbTjY7o9b-V4Dd6Hb_rTjZNI2QReH4rkOLVbPOktz4bOwwYbJyz5rKGlouOQ0Gf_YdexjmFsl6hFG8b0cEiyHeUKUfNybr9MAz04rPe-ayLz_qXz_q6ND39e419y29jCyB2QC6lcvz05-87ZH8CTjK29w</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Uijen, M. J. M.</creator><creator>Derks, Y. H. W.</creator><creator>Merkx, R. I. J.</creator><creator>Schilham, M. G. M.</creator><creator>Roosen, J.</creator><creator>Privé, B. M.</creator><creator>van Lith, S. A. M.</creator><creator>van Herpen, C. M. L.</creator><creator>Gotthardt, M.</creator><creator>Heskamp, S.</creator><creator>van Gemert, W. A. M.</creator><creator>Nagarajah, J.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20211201</creationdate><title>PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports</title><author>Uijen, M. J. M. ; Derks, Y. H. W. ; Merkx, R. I. J. ; Schilham, M. G. M. ; Roosen, J. ; Privé, B. M. ; van Lith, S. A. M. ; van Herpen, C. M. L. ; Gotthardt, M. ; Heskamp, S. ; van Gemert, W. A. M. ; Nagarajah, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-1695b019289e68a3a8a01c07f14afe1d5649512fec115a0ac09fef73d1c013ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>Brain cancer</topic><topic>Breast cancer</topic><topic>Cardiology</topic><topic>Computed tomography</topic><topic>Dipeptides</topic><topic>Glioblastoma</topic><topic>Hepatocellular carcinoma</topic><topic>Heterocyclic Compounds, 1-Ring</topic><topic>Humans</topic><topic>Imaging</topic><topic>Immunohistochemistry</topic><topic>Kidney cancer</topic><topic>Lung cancer</topic><topic>Lung carcinoma</topic><topic>Lutetium isotopes</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nuclear Medicine</topic><topic>Oncology</topic><topic>Oncology – General</topic><topic>Oral cancer</topic><topic>Orthopedics</topic><topic>Patients</topic><topic>Positron emission</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Prostatic Neoplasms, Castration-Resistant</topic><topic>Radioisotopes</topic><topic>Radiology</topic><topic>Renal cell carcinoma</topic><topic>Review</topic><topic>Review Article</topic><topic>Salivary gland</topic><topic>Salivary glands</topic><topic>Side effects</topic><topic>Solid tumors</topic><topic>Therapy</topic><topic>Thyroid cancer</topic><topic>Tomography</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uijen, M. J. M.</creatorcontrib><creatorcontrib>Derks, Y. H. W.</creatorcontrib><creatorcontrib>Merkx, R. I. J.</creatorcontrib><creatorcontrib>Schilham, M. G. M.</creatorcontrib><creatorcontrib>Roosen, J.</creatorcontrib><creatorcontrib>Privé, B. M.</creatorcontrib><creatorcontrib>van Lith, S. A. M.</creatorcontrib><creatorcontrib>van Herpen, C. M. L.</creatorcontrib><creatorcontrib>Gotthardt, M.</creatorcontrib><creatorcontrib>Heskamp, S.</creatorcontrib><creatorcontrib>van Gemert, W. A. M.</creatorcontrib><creatorcontrib>Nagarajah, J.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uijen, M. J. M.</au><au>Derks, Y. H. W.</au><au>Merkx, R. I. J.</au><au>Schilham, M. G. M.</au><au>Roosen, J.</au><au>Privé, B. M.</au><au>van Lith, S. A. M.</au><au>van Herpen, C. M. L.</au><au>Gotthardt, M.</au><au>Heskamp, S.</au><au>van Gemert, W. A. M.</au><au>Nagarajah, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>48</volume><issue>13</issue><spage>4350</spage><epage>4368</epage><pages>4350-4368</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [
177
Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [
177
Lu]Lu-PSMA is generally well tolerated due to its limited side effects. While PSMA is highly overexpressed in prostate cancer cells, varying degrees of PSMA expression have been reported in other malignancies as well, particularly in the tumor-associated neovasculature. Hence, it is anticipated that PSMA-RLT could be explored for other solid cancers. Here, we describe the current knowledge of PSMA expression in other solid cancers and define a perspective towards broader clinical implementation of PSMA-RLT. This review focuses specifically on salivary gland cancer, glioblastoma, thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. An overview of the (pre)clinical data on PSMA immunohistochemistry and PSMA PET/CT imaging is provided and summarized. Furthermore, the first clinical reports of non-prostate cancer patients treated with PSMA-RLT are described.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>34120192</pmid><doi>10.1007/s00259-021-05433-w</doi><tpages>19</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2021-12, Vol.48 (13), p.4350-4368 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8566635 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antigens Brain cancer Breast cancer Cardiology Computed tomography Dipeptides Glioblastoma Hepatocellular carcinoma Heterocyclic Compounds, 1-Ring Humans Imaging Immunohistochemistry Kidney cancer Lung cancer Lung carcinoma Lutetium isotopes Male Medical imaging Medicine Medicine & Public Health Nuclear Medicine Oncology Oncology – General Oral cancer Orthopedics Patients Positron emission Positron Emission Tomography Computed Tomography Prostate cancer Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - radiotherapy Prostatic Neoplasms, Castration-Resistant Radioisotopes Radiology Renal cell carcinoma Review Review Article Salivary gland Salivary glands Side effects Solid tumors Therapy Thyroid cancer Tomography Tumors |
| title | PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T00%3A09%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PSMA%20radioligand%20therapy%20for%20solid%20tumors%20other%20than%20prostate%20cancer:%20background,%20opportunities,%20challenges,%20and%20first%20clinical%20reports&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Uijen,%20M.%20J.%20M.&rft.date=2021-12-01&rft.volume=48&rft.issue=13&rft.spage=4350&rft.epage=4368&rft.pages=4350-4368&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-021-05433-w&rft_dat=%3Cproquest_pubme%3E2540723820%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2592763805&rft_id=info:pmid/34120192&rfr_iscdi=true |